



US009718880B2

(12) **United States Patent**  
**Bell et al.**

(10) **Patent No.:** **US 9,718,880 B2**  
(45) **Date of Patent:** **\*Aug. 1, 2017**

- (54) **TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT**
- (71) Applicant: **Alexion Pharmaceuticals, Inc.**, New Haven, CT (US)
- (72) Inventors: **Leonard Bell**, Woodbridge, CT (US); **Russell P. Rother**, Oklahoma City, OK (US); **Mark J. Evans**, Radnor, PA (US)
- (73) Assignee: **Alexion Pharmaceuticals, Inc.**, New Haven, CT (US)
- (\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.  
  
This patent is subject to a terminal disclaimer.

2003/0049260	A1	3/2003	Bell	
2003/0049683	A1	3/2003	Bowdish et al.	
2004/0038308	A1	2/2004	Rother et al.	
2004/0219147	A1	11/2004	Bell	
2004/0253242	A1	12/2004	Bowdish et al.	
2005/0036991	A1	2/2005	Fodor	
2005/0169921	A1	8/2005	Bell et al.	
2005/0191298	A1	9/2005	Bell et al.	
2005/0221382	A1	10/2005	Rother	
2005/0226870	A1	10/2005	Wang et al.	
2005/0271660	A1*	12/2005	Wang	C07K 16/18 424/144.1
2006/0057679	A1	3/2006	O'Keefe et al.	
2006/0263349	A1	11/2006	McCutcheon et al.	
2007/0116710	A1	5/2007	Bell et al.	
2009/0028850	A1*	1/2009	Rother	C07K 16/18 424/133.1
2009/0220508	A1	9/2009	Bell et al.	
2010/0068202	A1	3/2010	Bell et al.	
2011/0086040	A1	4/2011	Bell et al.	
2012/0237515	A1	9/2012	Bell et al.	
2012/0308559	A1	12/2012	Bell et al.	
2016/0376355	A1	12/2016	Bell et al.	
2017/0015741	A1	1/2017	Bell et al.	

(21) Appl. No.: **15/148,839**

**FOREIGN PATENT DOCUMENTS**

(22) Filed: **May 6, 2016**

CA	WO 2005110481	A2 *	11/2005	.....	C07K 16/18
EP	0411306	A1	2/1991		
WO	2004/029207	A2	4/2004		
WO	2005074607	A2	8/2005		
WO	2005110481	A2	11/2005		
WO	2007002571	A2	1/2007		
WO	2007005612	A2	1/2007		

(65) **Prior Publication Data**  
US 2016/0244516 A1 Aug. 25, 2016

**Related U.S. Application Data**

(63) Continuation of application No. 13/426,973, filed on Mar. 22, 2012, now abandoned, which is a continuation of application No. 12/225,040, filed as application No. PCT/US2007/006606 on Mar. 15, 2007, now abandoned.

**OTHER PUBLICATIONS**

Hillmen et al. "eFFECT of eCULIZUMAB on hEMOLYSIS and Transfusion Requirements in Patients With Paroxysmal Nocturnal Hemoglobinuria" *nejm* 350(6), 2004, pp. 552-559.\*  
Hillmen et al. "Effect of Eculizumab on Hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria" *NEJM*, 350; 6, 2004, pp. 552-559.\*

- (51) **Int. Cl.**  
**A61K 39/00** (2006.01)  
**A61K 9/00** (2006.01)  
**C07K 16/18** (2006.01)  
**C07K 19/00** (2006.01)  
**A61K 31/7105** (2006.01)  
**A61K 38/00** (2006.01)

(Continued)

*Primary Examiner* — Daniel E Kolker  
*Assistant Examiner* — James Rogers  
(74) *Attorney, Agent, or Firm* — Tara Rahemba, Esq.; Jane E. Remillard, Esq.; Jill Gorny Sloper, Esq.

(52) **U.S. Cl.**  
CPC ..... **C07K 16/18** (2013.01); **A61K 9/0019** (2013.01); **A61K 31/7105** (2013.01); **A61K 38/00** (2013.01); **A61K 2039/505** (2013.01); **C07K 2317/24** (2013.01); **C07K 2317/51** (2013.01); **C07K 2317/515** (2013.01); **C07K 2317/565** (2013.01)

(57) **ABSTRACT**

Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH.

(58) **Field of Classification Search**  
None  
See application file for complete search history.

(56) **References Cited**  
U.S. PATENT DOCUMENTS

4,686,100	A	8/1987	Raffin et al.	
5,135,916	A	8/1992	Sims et al.	
5,660,825	A	8/1997	Sims et al.	
6,355,245	B1*	3/2002	Evans	C07K 14/472 424/130.1



(56)

## References Cited

## OTHER PUBLICATIONS

Appel et al. "New approaches to the treatment of glomerular diseases" *Kidney International* (2006) 70, S45-S50.\*

69 Studies for eculizumab for clinical trials.gov, printed Feb. 28, 2017, pp. 1-3.\*

Clinical Trials Identifier: NCT0098280, "Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria" Jun. 23, 2005, pp. 1-4.\*

Safety and Effectiveness of h5G1.1-mAb for dermatomyositis clinicaltrials.gov identifier NCT00005571, Apr. 25, 2000, pp. 1-4.\*

Alexion Mariana Kaplan "Eculizumab" Current Opinion in Investigational Drugs 2002, 3(7): 10107-1023.\*

Adis International Limited, "Eculizumab: 5G1.1, h5G1.1, Long-Acting Anti-C5 Monoclonal Antibody 5G1-1, Long-Acting Anti-C5 Monoclonal Antibody 5G1.1," *Drugs in Research and Development*, vol. 8 (1); 61-68 (2007).

Rather et al., "Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria," *Nature Biotechnology*, 25 (11) 1256-1264 (2007).

Alexion Pharma K.K. "Report on the Deliberation Results" for "Solids for intravenous infusion 300 mg", Mar. 5, 2010, pp. 1-105.

Alexion Pharmaceuticals Inc., "Alexion completes enrollment in Ph II kidney disease trial," Market letter (Feb. 25, 2002), 2 pages.

Alexion Pharmaceuticals Inc., "Alexion Completes Enrollment in Phase II Membranous Nephritis Clinical Trial with 5G1.1; 5G1.1 Receives Orphan Drug Designation in Membranous Nephritis," PR Newswire, Feb. 20, 2012, 3 pages.

Alexion Pharmaceuticals Inc., "Alexion issued C5 complement inhibitor patent for inflammatory diseases," *ESPICOM Pharmaceutical and Medical Device News* (Mar. 19, 2002), 1 page.

Alexion Pharmaceuticals Inc., "Alexion Issued Key C5 Complement Inhibitor Patent for Inflammatory Diseases," PR Newswire (Mar. 15, 2002) 3 pages.

Alexion Pharmaceuticals Inc., "Alexion Pharmaceuticals Reports Second Quarter and First Half Results," PR Newswire [New York] (Mar. 8, 2001) 8 pages.

Alexion Pharmaceuticals Inc., "Alexion Pharmaceuticals Reports Second Quarter and First Half Results;—Quarter Highlighted by Successful Revision of Pexelizumab Collaboration With Procter & Gamble Pharmaceuticals and Commencement of Phase III Pivotal PRIMO-CABG Trial," PR Newswire, Mar. 8, 2002, 6 pages.

Alexion Pharmaceuticals Inc., "Company reports second quarter, first-half results," *Biotech Week* (Apr. 10, 2002), 2 pages.

Alexion Pharmaceuticals Inc., "Eculizumab Alexion clinical data (phase III) (PNH)," *R & D Focus Drug News* (Feb. 6, 2006), 2 pages.

Alexion Pharmaceuticals Inc., "Eculizumab Alexion clinical data (PNH)," *R & D Focus Drug News* (Jan. 30, 2006), 2 pages.

Alexion Pharmaceuticals Inc., "Eculizumab Alexion completes enrollment for phase III PNH trial," *R & D Focus Drug News*, (Apr. 25, 2005): 2 pages.

Alexion Pharmaceuticals Inc., "Eculizumab Alexion completes enrollment," *R & D Focus Drug News* (Feb. 17, 2003), 2 pages.

Alexion Pharmaceuticals Inc., "Eculizumab Alexion EMEA grants request for accelerated assessment procedure," *R & D Focus Drug News* (Aug. 28, 2006), 2 pages.

Alexion Pharmaceuticals Inc., "Eculizumab Alexion initiates second phase III study," *R & D Focus Drug News*, (Jan. 17, 2005), 2 pages.

Alexion Pharmaceuticals Inc., "Eculizumab Alexion plans phase III trials (paroxysmal nocturnal hemoglobinuria)," *R & D Focus Drug News* (Aug. 2, 2004), 2 pages.

Alexion Pharmaceuticals Inc., "Eculizumab Alexion Priority Review, USA (PNH)," *R & D Focus Drug News* (Nov. 20, 2006), 2 pages.

Alexion Pharmaceuticals Inc., "Kidney Disease; Enrollment com-

Alexion Pharmaceuticals Inc., "Kidney Disease; Enrollment complete for phase II membranous nephritis clinical trial with 5G1.1," *Immunotherapy Weekly*, p. 18, (Apr. 10, 2002).

Alexion Pharmaceuticals Inc., "Eculizumab Alexion phase change III, USA, Europe Canada, Australia (PNH)," *R & D Focus Drug News* (Nov. 15, 2004): 2 pages.

BC Cancer Agency Cancer Drug Manual, Drug Name Alemtuzumab, Jun. 1, 2013, pp. 11.

Brekke, O. et al., "Therapeutic Antibodies for Human Diseases at the Dawn of the Twenty-First Century," *Nature Reviews, Drug Discovery*, vol. 2: 52-62 (2003).

ESPICOM Pharmaceutical and Medical Device News, "Eculizumab found to be well tolerated and efficacious during 52 weeks of treatment in PNH," (Jan. 2, 2007), 2 pages.

European Decision Revoking the European Patent (Art. 101(2). (3)(b) EPC). 11 pages. dated Jul. 1, 2014.

European Medicines Agency, EMA/HMPC/16633/2009 section 2, Historical Data on Medicinal Use, 2010, pp. 1-40.

Fung, M. et al., "Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits," *The Journal of Thoracic and Cardiovascular Surgery*, vol. 122(1):113-121 (2001).

Grounds of Appeal filed on Nov. 11, 2014 in the related European Opposition, European Patent No. 1720571, pp. 1-15.

Hale, et al., "Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration," (2004) *Blood* 224(4), pp. 948-955.

Martin, F. et al., "Pathogenic Roles of B Cells in Human Autoimmunity: Insights from the Clinic," *Immunity*, vol. 20: 517-527 (2004).

Mollnes, T. et al., "Strategies of therapeutic complement inhibition," *Molecular Immunology*, vol. 43: 107-121 (2006).

Mueller, J., "Humanized Porcine VCAM-Specific Monoclonal Antibodies with Chimeric IgG2/G4 Constant Regions Block Human Leukocyte Binding to Porcine Endothelial Cells," *Molecular Immunology*, vol. 34(6): 441-452 (1997).

Dsborne, R., "Alexion Offers Early, Mixedphase III Data for Heart Drug," *Bioworld Today*, vol. 14, Issue 151 (Aug. 6, 2003), 3 pages.

Dsborne, J. et al., "Current methods for the generation of human antibodies for the treatment of autoimmune diseases," *Drug Discovery Today*, vol. 8 (18): 845-851 (2003).

Other News to Note, *Bioworld Today* (Aug. 9, 2002): 5 pages.

Pierangeli, S. et al., "Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia," *Arthritis & Rheumatology*, vol. 52, Issue 7: 2120-2124(2005).

Ricklin, D. et al., "Complement-targeted therapeutics," *Nature Biotechnology*, vol. 25(11): 1265-1275 (2007).

U.S. Appl. No. 15/260,888, filed Sep. 9, 2016, Leonard Bell.

U.S. Appl. No. 15/284,015, filed Oct. 3, 2016, Leonard Bell.

U.S. Appl. No. 15/260,888, filed Dec. 22, 2016, J. Rogers.

U.S. Appl. No. 15/260,888, filed Oct. 27, 2016, J. Rogers.

U.S. Appl. No. 15/284,015, filed Nov. 1, 2016, J. Rogers.

U.S. Appl. No. 13/335,518, filed Aug. 22, 2016, P. Gambel.

U.S. Appl. No. 13/426,973, filed Mar. 22, 2012, Leonard Bell.

U.S. Appl. No. 12/225,040, filed May 13, 2009, Leonard Bell.

U.S. Appl. No. 12/621,792, filed Nov. 19, 2009, Leonard Bell.

U.S. Appl. No. 10/771,552, filed Feb. 3, 2004, Leonard Bell.

U.S. Appl. No. 11/050,543, filed Feb. 3, 2005, Leonard Bell.

U.S. Appl. No. 11/595,118, filed Nov. 8, 2006, Leonard Bell.

U.S. Appl. No. 12/902,617, filed Oct. 12, 2010, Leonard Bell.

U.S. Appl. No. 13/335,518, filed Dec. 22, 2011, Leonard Bell.

U.S. Appl. No. 13/426,973, filed Jan. 27, 2014, J. Rogers.

U.S. Appl. No. 13/426,973, filed May 31, 2013, J. Rogers.

U.S. Appl. No. 13/426,973, filed Aug. 20, 2012, J. Rogers.

U.S. Appl. No. 12/225,040, filed Sep. 22, 2011, J. Rogers.

U.S. Appl. No. 12/225,040, filed Jun. 1, 2011, J. Rogers.

U.S. Appl. No. 12/225,040, filed Apr. 11, 2011, J. Rogers.

U.S. Appl. No. 12/621,792, filed Sep. 30, 2010, P. Gambel.

U.S. Appl. No. 10/771,552, filed Dec. 22, 2008, F. Vandervegt.

U.S. Appl. No. 10/771,552, filed Mar. 21, 2008, F. Vandervegt.

(56)

## References Cited

## OTHER PUBLICATIONS

- U.S. Appl. No. 10/771,552, filed Sep. 26, 2007, F. Vandervegt.  
 U.S. Appl. No. 11/050,543, filed Jul. 9, 2010, P. Gambel.  
 U.S. Appl. No. 11/050,543, filed Apr. 2, 2008, F. Vandervegt.  
 U.S. Appl. No. 11/050,543, filed Oct. 10, 2007, F. Vandervegt.  
 U.S. Appl. No. 11/050,543, filed Jun. 11, 2007, F. Vandervegt.  
 U.S. Appl. No. 11/595,118, filed Jan. 21, 2011, P. Gambel.  
 U.S. Appl. No. 11/595,118, filed Oct. 5, 2010, P. Gambel.  
 U.S. Appl. No. 11/595,118, filed Jul. 7, 2010, P. Gambel.  
 U.S. Appl. No. 11/595,118, filed Apr. 3, 2009, F. Vandervegt.  
 U.S. Appl. No. 12/902,617, filed Jun. 23, 2011, P. Gambel.  
 U.S. Appl. No. 12/902,617, filed Apr. 4, 2011, P. Gambel.  
 U.S. Appl. No. 13/335,518, filed Sep. 12, 2014, P. Gambel.  
 U.S. Appl. No. 13/335,518, filed Feb. 6, 2014, P. Gambel.  
 U.S. Appl. No. 13/335,518, filed Nov. 7, 2013, P. Gambel.
- Alexion receives FDA, European approval for orphan drug status of new treatment for paroxysmal nocturnal hemoglobinuria, *Transplant News*, Jan. 15, 2004, XP002497241; Retrieved from the world wide web at [findarticles.com/p/articles/mi\\_mOYUG/is\\_1\\_14/ai\\_17208612](http://findarticles.com/p/articles/mi_mOYUG/is_1_14/ai_17208612) [retrieved on Sep. 25, 2008].
- "Alexion Reports Presentation of Membranous Nephritis Clinical Trails"; [online]; Alexion Pharmaceuticals: News; [Retrieved on Jun. 17, 2003]. Retrieved from the world wide web at [alexionpharm.com/news/sub\\_press.cfm?prid=241&selectyear=2002](http://alexionpharm.com/news/sub_press.cfm?prid=241&selectyear=2002).
- Araten, et al., "High incidence of thrombosis in African-American and Latin-American patients with paroxysmal nocturnal haemoglobinuria," *Thromb Haemost*, vol. 93:88-91 (2005).
- Audebert et al., "Cerebral ischemic infarction in paroxysmal nocturnal hemoglobinuria," *J. Neurol.*, vol. 252:1379-2565 (2005).
- Brodsky, "New Insights into paroxysmal nocturnal hemoglobinuria," *Hematology* 516:24-28 (2006).
- Cella, D et al., "Linking Outcomes Management to Quality-of-Life Measurement, Oncology," *Williston Park*, vol. 11 (11A): 232-235 (1997).
- Clague et al, "A low-hemolysis blood aspirator conserves blood during surgery," *Biomed. Instrum. Technol.*, vol. 29 (5):419-424 (1995).
- Clinics, Biotechnology News*, vol. 24(30):10 (2004).
- Collard et al., "Endothelial nuclear factor-KB translocation and vascular cell adhesion molecule-1 induction by complement: inhibition with anti-human C5 therapy or cGMP analogues," *Art. Thromb. Vas.*, vol. 19:2623-2629 (1999).
- Sierra G. et al., "Vaccine against group B Neisseria meningitidis: Protection trial and mass vaccination results in Cuba", *NIPH Annals* 1991 NO, vol. 14(2):195-210, (1991) ISSN: 0332-5652.
- Corvini M. et al., "Complement C7 deficiency presenting as recurrent aseptic meningitis," Database accession No. NLM15328683, 1 page (2004) Database Medline [Online] US National Library of Medicine (NLM), Bethesda, MD, US; Oct. 1992 (Oct. 1992).
- "Alexion Announces Presentation of Preliminary Results from Phase I Pilot Study of Eculizumab Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria"; [online]; Alexion Pharmaceuticals: News; [Retrieved on Jun. 18, 2003]. Retrieved from the world wide web at [alexionpharmaceuticals.com/news/sub\\_press.cfm?prid=242&selectyear=2002](http://alexionpharmaceuticals.com/news/sub_press.cfm?prid=242&selectyear=2002).
- "Alexion Announces Results of Clinical Trial in Paroxysmal Nocturnal Hemoglobinuria Presented at the American Society of Hematology Annual Meeting"; [online]; Alexion Pharmaceuticals, Inc.; [Retrieved on Jun. 17, 2003]; Retrieved from the world wide web at [noonanrusso.com/news/view\\_newsitem.aspx?ItemID=382](http://noonanrusso.com/news/view_newsitem.aspx?ItemID=382).
- Alexion Pharmaceuticals: Complement Inhibitors; [online]; [Retrieved on Jun. 17, 2003]; Retrieved from the world wide web at [alexionpharm.com/techplat/complement.cfm](http://alexionpharm.com/techplat/complement.cfm).
- Alexion Pharmaceuticals Signs Agreement with Lonza Biologics for Commercial Manufacturing; [online]; Alexion Pharmaceuticals
- Morris J T et al: "Recurrence of neisserial meningococemia due to deficiency of terminal complement Component," Database accession No. NLM1411724, Database Medline [Online] US National Library of Medicine (NLM), Bethesda, MD, US; Oct. 1992 (Oct. 1992).
- Figuroa and Densen, "Infectious Diseases Associated with Complement Deficiencies," *Clinical Microbiology Reviews*, vol. 4(3): 359-395 (1991).
- Fitch et al., "Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass," *Circulation* 100 (25):2499-2506 (1999).
- Garba and Ubom, "Total serum lactate dehydrogenase activity in acute Plasmodium falciparum malaria infection," *Singapore Medical J.* 46(11 ):632-634 (2005).
- Garcia et al. "Effect of preservatives on IgG aggregation, complement-activating effect and hypotensive activity of horse; polyvalent antivenom used in snakebite envenomation," *Biologicals*, vol. 30:143-151(2002).
- Genes and Disease; [online]; Paroxysmal nocturnal hemoglobinuria; [Retrieved on 2003-06017]. Retrieved from the world wide web at [ncbi.nlm.nih.gov/disease/PNH.html](http://ncbi.nlm.nih.gov/disease/PNH.html).
- Hall et al., "Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH)," *Blood*, vol. 102 3587-3591 (2003).
- Harding, J. "Eculizumab," *Drugs of the Future, Pro US Science, ES*, vol. 29(7): 673-676, XP008113000 (2004).
- Hill et al., "Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria," *Haematology*, 90(12): Abstract #ECR40; (2005).
- Hill et al., "Sustained Control of Hemolysis and Symptoms and Reduced Transfusion Requirements over a Period of 2 Years in Paroxysmal Nocturnal Hemoglobinuria (PNH) with Eculizumab Therapy," *Blood*, vol. 104:Abstract 2823 (2004) with ASH poster final 2004.ppt.
- Hill et al., "Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria," *Blood*, vol. 106: 2559-2565 (2005).
- Hill, et al., "Protection of erythrocytes from human complement-mediated lysis by membranetargeted recombinant soluble CD59: a new approach to PNH therapy," *Blood* 107(5):2131-2137 (2006).
- Hillmen et al. "Effect of Eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal Hemoglobinuria," *N Engl J Med*, vol. 350(6):552-559 (2004).
- Hill et al. "Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria" *Haematologica*, vol. 90(online): 111-113 (2005).
- Hill, et al., "Nitric oxide consumption and pulmonary hypertension in patients with paroxysmal nocturnal hemoglobinuria," *Blood* 106(11):Abstract 1046 (2005) XP002482085—47th Annual Meeting of the American Society of Hematology, Dec. 10-13, 2005.
- Hill, "Eculizumab, for the treatment of paroxysmal nocturnal hemoglobinuria," *Clin. Adv. In Hermal. & Onc.*, XP0015384263 (11):849-850 (2005).
- Hillman et al., "Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria," *Blood* 110(12):4123-4128 (2007).
- Hillmen, et al., "Eculizumab, a C5 Complement-blocking Antibody, Abolishes Hemolysis and Renders Hemolytic Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Transfusion Independent," 44th ASH Annual Meeting, *Blood* 100 (11) (Abstract No. 154) (2002).
- Meyers, et al., "Management Issues in Paroxysmal Nocturnal Hemoglobinuria," *International Journal of Hematology*, 17:125-132 (2003).
- Hillmen, et al., "The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria," *N Engl J Med.*, vol. 355: 1233-1243 (2006).
- Hillmen, et al., "The terminal complement inhibitor eculizumab reduces thrombosis in patients with paroxysmal nocturnal hemoglobinuria," *Blood* 108(11 ):Abstract 123 (2006)

(56)

**References Cited**

## OTHER PUBLICATIONS

Hillmen, et al., Eculizumab, a C5 complement blocking antibody, is the first therapy to reduce transfusion requirements in patients with paroxysmal nocturnal haemoglobinuria (PNH); *British Journal of Haematology*, vol. 121, No. Supplement 1, p. 87, XP009144758 (2003). 43rd Annual Scientific Meeting of the British Society for Haematology, Apr. 7-9, 2003.

Inoue et al., "Molecular genetics of paroxysmal nocturnal hemoglobinuria," *Int J Hematol.*, Feb 77(2):107-112 (2003).

Int PNH Interest GRP: Diagnosis management of paroxysmal nocturnal hemoglobinuria, *Blood*, vol. 106 (12):3699-3709, (2005) XP002482081.

Jasinski, et al. "A novel mechanisms of complement-independent clearance of red cells deficient in glycosyl phosphatidylinositol-linked proteins" *Blood*, vol. 103(7):2827-2834 (2004).

Kaplan "Eculizumab Alexion," *Current Opinion in Invest. Drugs*, vol. 3(7),1017-1023 (2002).

Kato et al. "Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes," *Blood Reviews*, vol. 21: 37-47 (2007).

Kinoshita, Taroh. "Molecular pathogenesis of Paroxysmal Nocturnal Haemoglobinuria," XXVIth World Congress of the International Society of Haematology, Singapore, Aug. 25-29, 1996.

Lee et al., "Neisseria meningitidis Bacteremia in Association with Deficiency of the Sixth Component of Complement," *Infection and Immunity*, vol. 24(3): 656-660 (1979).

Luzzatto, et al., Recent advances in biological and clinical aspects of paroxysmal nocturnal hemoglobinuria, *Intl. J. Hematol.* 84:104-112 (2006).

Macneil, "Eculizumab could be paroxysmal nocturnal hemoglobinuria breakthrough," MacNeil, J.S., 44th Annual Meeting of the American Society of Hematology, Medscape Medical News, (Dec. 13, 2002); [online]; Medscape from WebMD; [Retrieved on Jun. 17, 2003. Retrieved from the world wide web at medscape.com/viewarticle/446336 XP009106338.

Merck Manual of Diagnosis and Therapy (The), Seventeenth Edition, Chapter 127 Anemias, 849-883 (1999).

Hillmen et al., "Eculizumab, a C5 Complement-Blocking Antibody, Controls Hemolysis in Paroxysmal Nocturnal Hemoglobinuria (PNH) with Responses Maintained over prolonged Period of Therapy" *Journal of the American Society of Hematology*, vol. 102(11), Abstract 1858 (2003).

Hillmen et al., "Eculizumab, a C5 complement-blocking antibody, controls haemolysis in paroxysmal nocturnal haemoglobinuria (PNH) with responses maintained over a prolonged period of therapy," *British Journal of Haematology*, vol. 125 (Suppl. 1): 1-72, Abstract 5 (2004).

U.S. Appl. No. 15/260,888, filed Apr. 11, 2017, J. Rogers.

U.S. Appl. No. 15/284,015, filed Apr. 11, 2017, J. Rogers.

Mortazavi et al., "The spectrum of PIG-A gene mutations in a plastic anemia/paroxysmal nocturnal hemoglobinuria (AAIPNH): a high incidence of multiple mutations and evidence of a mutational hot spot," *Blood* 101 2833-2841 (2003).

Moyo et al., "Natural history of paroxysmal nocturnal hemoglobinuria using modern diagnostic assays," *British J Haematology* 126, 133-138 (2004).

Notice of Opposition for EP Patent No. 1720571, dated Mar. 18, 2013.

Parker et al., Diagnosis and management of paroxysmal nocturnal hemoglobinuria, *Blood*, 106(12):3699-3709 (2005).

Paroxysmal nocturnal hemoglobinuria, included; PNH, included phosphatidylinositol glycan, class A, pseudogene 1, included; pigap1, included piga-related processed gene, included [online]. OM 1M-Online Medelian Inheritance in Man; John Hopkins University; [Retrieved on Jun. 18, 2003]. Retrieved from the world wide web at ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=OMIM&dopt=detailed . . .

Reiter et al., "Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease," *Nature Medicine* 8 (12):1383-1389 (2002).

Richards et al., "Evolution of GPI-Deficient Clones Predicts Clinical Course in Paroxysmal Nocturnal Haemoglobinuria," *Blood*, 104:Abstract 172 (2004).

Rodary et al., "Patient preference for either the EORTC QLQ-C30 or the FACIT Quality of Life (QOL) measures: a study performed in patient suffering from carcinoma of an unknown primary site (CUP)," *European Journal of Cancer*, vol. 40, pp. 521-528 (2004).

Rosse et al., Immune-mediated hemolytic anemia, *Hematology Am Soc Hematol Educ. Program*, 48-62 (2004) XP002497825.

Rother et al., Eculizumab, a C5 complement-blocking antibody, abolishes hemolysis and reduces transfusion dependency in patients with paroxysmal nocturnal hemoglobinuria (PNH), *Molecular Immunology*, vol. 40(2-4), p. 197; XP009163498, (2003).

Rother et al., The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin, *JAMA* 293 (13):1653-1662 (2005).

Stebler et al., High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study, *Exp. Hematol.* 18:1204-1208 (1990).

Strauss et al. "Alternative pathway of complement in sickle cell disease," *Pediat. Res.*, vol. 11:285-289 (1977).

Stuart et al., "Sickle-cell disease," *Lancet*, vol. 364:1343-60 (2004).

Tang and Pikal, Design of Freeze-Drying Processes for Pharmaceuticals: Practical Advice, *Pharmaceutical Research*, vol. 21 (2):191-200 (2004).

Thomas et al., Inhibition of complement activity by humanized anti-C5 antibody and single chain Fv, *Mol.Imm.* 33 (17-18):1389-1401, XP002262113 (1996).

Vakeva, et al., "Myocardial infarction and apoptosis after myocardial ischemia and reperfusion," *Circulation* 97:2259-2267 (1998).

\* cited by examiner




FIGURE 1A



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.